New weekly shot could help diabetics shed pounds

NCT ID NCT07104383

Disease control Sponsor: Viking Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing a weekly injection called VK2735 to help people with type 2 diabetes who are overweight or obese lose weight. About 1,100 participants will receive either the drug or a placebo for 78 weeks. The study measures how much weight they lose and whether the treatment is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: VK2735 (a weekly injection that mimics natural hormones to reduce appetite and improve blood sugar)
What this could lead to: If successful, this could provide a new treatment option for significant weight loss in people with type 2 diabetes, potentially improving blood sugar control and reducing obesity-related health risks.
What could go wrong: This is a late-stage trial, but results are not yet available. Side effects common to similar drugs include nausea, vomiting, and diarrhea. Long-term safety and effectiveness beyond 78 weeks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥27 kg/m2 3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists Exclusion Criteria: 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed \>1 year prior to screening) 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line) 5. Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM) 6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL 7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization 8. Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment 9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) 10. History of acute or chronic pancreatitis 11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Weight loss

Contacts and locations

Locations

Viking Clinical Site #2001

Methuen, Massachusetts, 01844, United States
Viking Clinical Site #2002

Ogden, Utah, 84405, United States
Viking Clinical Site #2003

Cooper City, Florida, 33024, United States
Viking Clinical Site #2004

Knoxville, Tennessee, 37909, United States
Viking Clinical Site #2005

Chandler, Arizona, 85210, United States
Viking Clinical Site #2006

Chicago, Illinois, 60607, United States
Viking Clinical Site #2007

Austin, Texas, 78705, United States
Viking Clinical Site #2008

Nashville, Tennessee, 37203, United States
Viking Clinical Site #2009

Louisville, Kentucky, 40213, United States
Viking Clinical Site #2010

Butte, Montana, 59701, United States
Viking Clinical Site #2011

Port Orange, Florida, 32127, United States
Viking Clinical Site #2012

Ocoee, Florida, 34761, United States
Viking Clinical Site #2013

Clearwater, Florida, 33756, United States
Viking Clinical Site #2014

Lake Forest, California, 92630, United States
Viking Clinical Site #2015

San Antonio, Texas, 78229, United States
Viking Clinical Site #2016

Kansas City, Missouri, 64131, United States
Viking Clinical Site #2017

Flagstaff, Arizona, 86001, United States
Viking Clinical Site #2018

Peoria, Arizona, 85381, United States
Viking Clinical Site #2019

Tucson, Arizona, 85711, United States
Viking Clinical Site #2020

Metairie, Louisiana, 70006, United States
Viking Clinical Site #2022

West Des Moines, Iowa, 50266, United States
Viking Clinical Site #2023

North Charleston, South Carolina, 29405, United States
Viking Clinical Site #2024

St. George, Utah, 84790, United States
Viking Clinical Site #2025

Woodstock, Georgia, 30189, United States
Viking Clinical Site #2026

Greensboro, North Carolina, 27410, United States
Viking Clinical Site #2027

Fargo, North Dakota, 58104, United States
Viking Clinical Site #2028

Greenville, South Carolina, 29607, United States
Viking Clinical Site #2029

Albuquerque, New Mexico, 87109, United States
Viking Clinical Site #2030

Columbus, Georgia, 31904, United States
Viking Clinical Site #2031

City of Saint Peters, Missouri, 63303, United States
Viking Clinical Site #2032

Westfield, New York, 14787, United States
Viking Clinical Site #2034

Reno, Nevada, 89511, United States
Viking Clinical Site #2035

Las Vegas, Nevada, 89148, United States
Viking Clinical Site #2036

Little Rock, Arkansas, 72211, United States
Viking Clinical Site #2037

Birmingham, Alabama, 35235, United States
Viking Clinical Site #2038

Ypsilanti, Michigan, 48197, United States
Viking Clinical Site #2039

Sandy City, Utah, 84094, United States
Viking Clinical Site #2040

Lexington, Kentucky, 40513, United States
Viking Clinical Site #2041

Spokane, Washington, 99218, United States
Viking Clinical Site #2043

Cincinnati, Ohio, 45219, United States
Viking Clinical Site #2044

Cleveland, Ohio, 44122, United States
Viking Clinical Site #2045

East Greenwich, Rhode Island, 02818, United States
Viking Clinical Site #2046

Houston, Texas, 77040, United States
Viking Clinical Site #2047

Abilene, Texas, 79606, United States
Viking Clinical Site #2048

Dallas, Texas, 75235, United States
Viking Clinical Site #2049

Dallas, Texas, 75230, United States
Viking Clinical Site #2050

Long Beach, California, 90815, United States
Viking Clinical Site #2051

Lincoln, California, 95648, United States
Viking Clinical Site #2052

Spring Valley, California, 91978, United States
Viking Clinical Site #2053

Montclair, California, 91763, United States
Viking Clinical Site #2054

Huntington Park, California, 90255, United States
Viking Clinical Site #2056

Palmetto Bay, Florida, 33157, United States
Viking Clinical Site #2057

West Palm Beach, Florida, 33407, United States
Viking Clinical Site #2058

Jacksonville, Florida, 32216, United States
Viking Clinical Site #2060

Lakewood Rch, Florida, 34211, United States
Viking Clinical Site #2061

Morehead City, North Carolina, 28857, United States
Viking Clinical Site #2062

Honolulu, Hawaii, 96814, United States
Viking Clinical Site #2063

Austin, Texas, 78131, United States
Viking Clinical Site #2064

Birmingham, Alabama, 35249, United States
Viking Clinical Site #2065

Lebanon, New Hampshire, 03756, United States
Viking Clinical Site #2066

Rockville, Maryland, 20854, United States
Viking Clinical Site #2067

Van Nuys, California, 91405, United States
Viking Clinical Site #2068

Panorama City, California, 91402, United States
Viking Clinical Site #2069

Lexington, Kentucky, 40509, United States
Viking Clinical Site #2070

Escondido, California, 92025, United States
Viking Clinical Site #2071

Chula Vista, California, 91911, United States
Viking Clinical Site #2072

Renton, Washington, 98057, United States
Viking Clinical Site #2074

Cincinnati, Ohio, 45242, United States
Viking Clinical Site #2075

Omaha, Nebraska, 68134, United States
Viking Clinical Site #2076

Lakeland, Florida, 33803, United States
Viking Clinical Site #2077

Lampasas, Texas, 76550, United States
Viking Clinical Site #2078

Manteca, California, 95336, United States
Viking Clinical Site #2079

Walnut Creek, California, 94598, United States
Viking Clinical Site #2080

Meridian, Idaho, 83642, United States
Viking Clinical Site #2082

Suffolk, Virginia, 23435, United States
Viking Clinical Site #2083

Fort Myers, Florida, 33912, United States
Viking Clinical Site #2085

San Antonio, Texas, 78222, United States
Viking Clinical Site #2086

San Juan, 00927, Puerto Rico
Viking Clinical Site #2087

Monroe, Louisiana, 71201, United States
Viking Clinical Site #2088

Albany, New York, 12205, United States
Viking Clinical Site #2089

Columbus, Ohio, 43215, United States
Viking Clinical Site #2091

Bellaire, Texas, 77401, United States
Viking Clinical Site #2092

Salt Lake City, Utah, 84107, United States
Viking Clinical Site #2093

Savannah, Georgia, 31406, United States
Viking Clinical Site #2094

Chevy Chase, Maryland, 20815, United States
Viking Clinical Site #2095

Marlton, New Jersey, 08009, United States
Viking Clinical Site #2096

Hartsdale, New York, 10530, United States
Viking Clinical Site #2097

Portland, Oregon, 97202, United States
Viking Clinical Site #2098

Arlington, Virginia, 22205, United States
Viking Clinical Site #2099

Wichita, Kansas, 67207, United States
Viking Clinical Site #2101

Fayetteville, North Carolina, 28304, United States
Viking Clinical Site #2102

Seabrook, Texas, 77586, United States
Viking Clinical Site #2106

Lafayette, Louisiana, 70508, United States
Viking Clinical Site #2107

Delray Beach, Florida, 33445, United States
Viking Clinical Site #2109

Tustin, California, 92780, United States
Viking Clinical Site #2110

Morehead City, North Carolina, 28557, United States
Viking Clinical Site #2111

Frisco, Texas, 75033, United States
Viking Clinical Site #2112

DeLand, Florida, 32720, United States
Viking Clinical Site #2113

Norman, Oklahoma, 73069, United States
Viking Clinical Site #2115

Winston-Salem, North Carolina, 27157, United States
Viking Clinical Site #2116

Atlanta, Georgia, 30329, United States
Viking Clinical Site #2117

Miami, Florida, 33122, United States
Viking Clinical Site #2118

Baton Rouge, Louisiana, 70808, United States
Viking Clinical Site #2119

Denver, Colorado, 80210, United States
Viking Clinical Site #2120

Rincon, Georgia, 31326, United States
Viking Clinical Site #2121

Clearwater, Florida, 33761, United States
Viking Clinical Site #2124

Brownsville, Texas, 78526, United States
Viking Clinical Site #2125

Springfield, Missouri, 65807, United States
Viking Clinical Site #2126

Portland, Oregon, 97210, United States
Viking Clinical Site #2127

Valparaiso, Indiana, 46383, United States
Viking Clinical Site #2128

Huntsville, Alabama, 35801, United States
Viking Clinical Site #2129

Lemon Grove, California, 91945, United States
Viking Clinical Site #2130

Mayagüez, 00680, Puerto Rico
Viking Clinical Site #2131

San Diego, California, 92103, United States
Viking Clinical Site #2132

Rolling Hills Estates, California, 90274, United States
Viking Clinical Site #2133

New York, New York, 10036, United States
Viking Clinical Site #2134

Myrtle Beach, South Carolina, 29572, United States
Viking Clinical Site #2135

Scottsdale, Arizona, 85260, United States
Viking Clinical Site #2137

Tulsa, Oklahoma, 74133, United States
Viking Clinical Site #2139

Baton Rouge, Louisiana, 70809, United States
Viking Clinical Site #2140

Gulfport, Mississippi, 39503, United States
Viking Clinical Site #2141

Charlotte, North Carolina, 28205, United States
Viking Clinical Site #2143

San Antonio, Texas, 78215, United States
Viking Clinical Site #2145

Rockville, Maryland, 20850, United States
Viking Clinical Site #2146

Indianapolis, Indiana, 46202, United States
Viking Clinical Site #2147

Sioux City, Iowa, 68776, United States
Viking Clinical Site #2148

Dayton, Ohio, 45420, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.